PLx Pharma Inc. Overview
Industry: Drug Manufacturers-Specialty & Generic
Sector: Healthcare
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey. On April 13, 2023, PLx Pharma Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated Read MorePLx Pharma Inc. is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.
PLx Pharma Inc.
Score
Recent News
Earnings Per Share
Score 4.00/5
PLx Pharma Inc. boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Drug Manufacturers-Specialty & Generic industry
, PERRIGO Co plc
, TPCO Holding Corp.
, Gelteq Ltd
are companies with high ratings.
Return on Equity
Score 3.30/5
PLx Pharma Inc. stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
In
Drug Manufacturers-Specialty & Generic industry
, PERRIGO Co plc
, TPCO Holding Corp.
, Gelteq Ltd
are companies with high ratings.
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
Net Margin
Score 0.57/5
PLx Pharma Inc.
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
In
Drug Manufacturers-Specialty & Generic industry
, PERRIGO Co plc
, TPCO Holding Corp.
, Gelteq Ltd
are companies with high ratings.
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
Leverage
Score 1.46/5
PLx Pharma Inc.
registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
have achieved high scores.
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
In
Drug Manufacturers-Specialty & Generic industry
, PERRIGO Co plc
, TPCO Holding Corp.
, Gelteq Ltd
are companies with high ratings.
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios
